Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19882338 | 0.83 | TSHR (0.35) | ALDH1A1 | |
| SCHEMBL18715951 | 0.80 | REN (0.32) | REN | |
| SCHEMBL18639285 | 0.80 | REN (0.32) | REN | |
| SCHEMBL20072154 | 0.80 | FFAR2 (0.30) | MMP1 | |
| SCHEMBL20204595 | 0.77 | BCHE (0.31) | BCHE | |
| SCHEMBL18459795 | 0.76 | — | — | |
| SCHEMBL27332695 | 0.76 | HDAC1 (0.37) | — | |
| SCHEMBL27332697 | 0.76 | HDAC1 (0.37) | — | |
| SCHEMBL27332702 | 0.74 | HDAC1 (0.35) | MMP1ALDH1A1BCHEFPR2AKT1 | |
| SCHEMBL27332716 | 0.74 | HDAC1 (0.35) | MMP1ALDH1A1BCHEFPR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10465013-B2 | Antibodies to quetiapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-05 | — | — | US | disclosed |
| US-20180105606-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105606-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | REN 1703/4885MMP1 3706/4885ALDH1A1 2245/4885 |
| US-10465013-B2 | Antibodies to quetiapine haptens and use thereof | HTR4, HTR3C, SLC6A4 | REN 1703/4885MMP1 3706/4885ALDH1A1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.